Alexion and Complement Pharma co-developing inhibitor for neurodegenerative disorders

Orphan status for Asceneuron’s tau modifier
Credit: Shutterstock.com/ Alexander Raths

Alexion Pharmaceuticals and Complement Pharma are partnering to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders.

C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following complement activation, and has the potential to treat a variety of central nervous system disorders.

Alexion will provide Complement Pharma with up to €14 million in milestone-dependent payments through Phase 1b development.

The agreement also provides Alexion with the option to acquire Complement Pharma during the term of the agreement.

“Alexion has been a pioneer in complement biology since the development of Soliris, the world’s first complement inhibitor, which has demonstrated the significant impact that C5 inhibition can have on several diseases caused by uncontrolled complement activation,” said John Orloff, Executive Vice President and Head of Research & Development at Alexion.

“This collaboration provides an exciting opportunity to expand on our more than two decades of complement expertise to potentially treat additional diseases by targeting C6, a different component of the complement system.”

Alexion and Complement Pharma will collaborate on the development program for CP010. The latter will be responsible for conducting preclinical and Phase 1 studies and for manufacturing CP010.

The phased agreement extends through the completion of Phase 1b development. Alexion has the option to acquire Complement Pharma during the term of the agreement.